Bristol Myers Squibb Foundation establishes first cohort of the Diversity in Clinical Trials Career Development Program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Bristol Myers Squibb Foundation, together with its partners, National Medical Fellowships and the American Association for Cancer Research, selected 52 physicians for its Diversity in Clinical Trials Career Development Program. These early-stage investigators are the first of 250 community-oriented clinical trialists who will be trained through the program by 2027.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone. 

Login